Apremilast – A Novel Treatment for Behcet’s Disease
DOI:
https://doi.org/10.66344/jpad.35.3.2025.3160Keywords:
Apremilast, Behcet’s disease, Oral ulcers, Genital ulcers, Orogenital, Novel therapyAbstract
Behcet's disease is a chronic inflammatory disease involving multi-organ system; it results from a complex interplay of genetic, environmental, infectious, and immunological factors, though its precise etiology remains unclear. The disease is categorized as neutrophilic dermatosis and the clinical manifestations occur due to vasculitis that affects blood vessels of all types and sizes. The disease affects many other organs specifically the eye, gastrointestinal system, central nervous system, joints, kidneys and vascular system. We report the case of an 18-year-old girl having Behcet’s disease for the past 4 years with typical recurrent oral aphthosis along with pharyngeal involvement leading to dysphagia and a large ulcerative lesion over labia majora. Notably, her condition showed a remarkable response to a premilasthighlighting its potential therapeutic role in refractory mucocutaneous manifestations of Behcet’s disease. This case underscores the expanding treatment landscape and the need for further investigation into targeted immunomodulatory therapies.References
Basnet M, Gautam K, Pathak BD, Phudong A, Gaire S, Bohara N, et al. Behcet's disease in an adult male from Nepal: a case report. Clin Case Rep. 2021; 9(10):e04912. Doi: 10.1002/ccr3.4912.
Alibaz-Oner F, Direskeneli H. Update on the Diag-nosis of Behçet's Disease. Diagnostics (Basel). 2022;13(1):41. Doi: 10.3390/diagnostics13010041.
Giannessi C, Smorchkova O, Cozzi D, Zantonelli G, Bertelli E, Moroni C, et al. Behçet’s disease: a radio-logical review of vascular and parenchymal pul-monary involvement. Diagnostics, 2022; 12(11):2868. Doi: 10.3390/diagnostics12112868.
Sadeghi A, Rostami M, Amraei G, Davatchi F, Sha-hram F, Karimi Moghaddam A, et al. Clinical man-ifestations of Behçet’s disease: a retrospective cross-sectional study. Mediterr J Rheumatol. 2023;34(1):53-60. Doi: 10.31138/mjr.34.1.53.
Vural S, Boyvat A. The skin in Behçet's disease: mucocutaneous findings and differential diagno-sis. J Eur Acad Dermatol Venereol. 2022. Doi:10.1002/jvc2.11.
Zhong Z, Liao W, Gao Y, Su G, Feng X, Yang P. Evaluation of sensitivity and specificity of diagnos-tic criteria for Behçet’s disease in the absence of a gold standard. Rheumatology (Oxford). 2022;61 (9):3667-3676. Doi: 10.1093/rheumatology/keac018.
Carmona-Rocha E, Rusiñol L, Puig L. Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology. Pharmaceutics. 2025;17(1):91. Doi: 10.3390/pharmaceutics17010091.
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, et al. Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study. RMD Open. 2022;8(2):e002235. Doi: 10.1136/rmdopen-2022-002235.
Wang Z, Zu X, Xiong S, Mao R, Qiu Y, Chen B, et al. The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease. Clin Ther. 2023;45(2):162-176.
Doi: 10.1016/j.clinthera.2023.01.004.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Pakistan Association of Dermatologists
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
